Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

CANNPAL ANIMAL THERAPEUTICS LIMITED

INVESTOR PRESENTATION - CANNPAL ANIMAL THERAPEUTICS LIMITED

ASX:CP1

CANNPAL ANIMAL THERAPEUTICS LIMITED

Health Care

CannPal Animal Therapeutics Limited (CP1) is a pet pharmaceutical Company that has identified an opportunity to benefit from the rapidly growing medical cannabis sector, by developing standardised and dosage controlled, regulatory approved pharmaceuticals, derived from the cannabis plant. The Company is established to research, develop and commercialise regulatory approved, cannabinoid-derived therapeutics, for the global animal health markets, with an initial focus on cats and dogs, in the United States, Europe, Australia and other emerging global markets.

Read more

Market Cap

10.24m

Price at Close

$0.11

4w avg. Volume

36.67k

4w avg. Turnover

$4.31k

Announcements
announcementt+2 movementdate
  • Notice of Annual General Meeting/Proxy Form

    Notice Of Meeting

  • +4.35%

    18 Oct 2020

+4.35%

18 Oct 2020
  • CannPal Animal Health Investment USA Presentation

    Periodic Reports

  • -7.69%

    12 Oct 2020

-7.69%

12 Oct 2020
  • CannPal Commences Product Registration in South Africa

    Progress Report · Market sensitive

  • -7.69%

    11 Oct 2020

-7.69%

11 Oct 2020
  • Appendix 4G

    Periodic Reports

  • 0.00%

    01 Oct 2020

0.00%

01 Oct 2020
  • Annual Report to Shareholders

    Periodic Reports

  • -4.76%

    23 Sep 2020

-4.76%

23 Sep 2020
  • Final Director's Interest Notice R Johnston

    Shareholder Details

  • -4.76%

    03 Sep 2020

-4.76%

03 Sep 2020
  • Board of Directors Change

    Company Administration

  • +4.35%

    28 Aug 2020

+4.35%

28 Aug 2020
  • Preliminary Final Report

    Periodic Reports · Market sensitive

  • 0.00%

    19 Aug 2020

0.00%

19 Aug 2020
  • Quarterly Cash Flow Report Market Update 30 June 2020

    Commitments test entity quarterly reports · Market sensitive

  • -3.85%

    29 Jul 2020

-3.85%

29 Jul 2020
  • DermaCann Reduces Atopic Dermatisis Symptoms in Dogs

    Progress Report · Market sensitive

  • -7.14%

    20 Jul 2020

-7.14%

20 Jul 2020
Market Data

Current Price

$0.11

52WK HIGH

$0.2

52WK LOW

$0.069

1YR RETURN

-15.38%

1YR RETURN VS. SECTOR

-32.59%

90 DAY RETURN

-12.00%

ASX RANK

1,700

/2,014

SECTOR RANK

29

/31

SHARES OUTSTANDING

93.13m
ASX:CP1

CANNPAL ANIMAL THERAPEUTICS LIMITED

Health Care

CannPal Animal Therapeutics Limited (CP1) is a pet pharmaceutical Company that has identified an opportunity to benefit from the rapidly growing medical cannabis sector, by developing standardised and dosage controlled, regulatory approved pharmaceuticals, derived from the cannabis plant. The Company is established to research, develop and commercialise regulatory approved, cannabinoid-derived therapeutics, for the global animal health markets, with an initial focus on cats and dogs, in the United States, Europe, Australia and other emerging global markets.

Read more

Market Cap

10.24m

Price at Close

$0.11

4w avg. Volume

36.67k

4w avg. Turnover

$4.31k

ASX:CP1 is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.